Synthetic Blood Substitutes and Blood Product Market Size, Trends and Insights By Source (Human Blood, Animal Blood, Synthetic Polymers, Stem Cells, Others), By Type (Perfluorocarbon Based Product (PFC), Haemoglobin Based Oxygen Carrier, Synthetic Platelet, Recombinant Factor, Blood Expander), By Installation Type (Cardiovascular Diseases, Anaemia, Organ Transplant, Injury and Trauma, Others), By End-User (Hospitals and Clinics, Blood Banks, Others), and By Region - Global Industry Overview, Statistical Data, Competitive Analysis, Share, Outlook, and Forecast 2025–2034
The global synthetic blood substitutes and blood product market was valued at USD 9.73 Bn in 2025 and is projected to reach USD 39.64 Bn by 2034, growing at a CAGR of 16.89%. North America is the largest regional market and Asia Pacific is growing fastest.
Reports Description
Global Synthetic Blood Substitutes and Blood Product Market size was valued at USD 9,729.94 Million in 2025 and is expected to reach USD 39,637.49 Million by 2034 at a CAGR of 16.89% during the forecast period 2025 -2034.
Synthetic blood products, including whole blood, platelets, red blood cells (RBCs), plasma, and cryoprecipitate, are important for treating situations like anemia, handling clotting disorders, and restoring blood extent during surgeries or trauma.
Synthetic substitute products like perfluorocarbon-based emulsions (PFCs) and hemoglobin-based oxygen carriers (HBOCs) are designed to replicate the oxygen-carrying feature of red blood cells. HBOCs use hemoglobin from diverse sources to transport oxygen in the body, while PFCs dissolve and release oxygen effectively.
Rising Awareness of the Benefits of Artificial Blood
The increasing awareness about artificial blood, coupled with low proportions of blood donors, is propelling the market growth. While manufacturing blood substitutes, bacteria as well as viruses can be eliminated. This helps to reduce the risk of infectious blood transfusion diseases, a major challenge in many regions of Sub-Saharan Africa.
The rise in studies and developments in the field of artificial blood is expected to greatly increase the global synthetic blood substitutes and blood product market.
Synthetic blood substitutes have various benefits, such as longer shelf existence, decreased threat of contamination, and no want for blood kind matching, which improves logistics and availability. Furthermore, the increasing need for alternatives to natural blood in clinical remedies and emergencies is expected to drive the demand for synthetic blood substitutes.
Increasing Use of Blood Substitutes in Organ Transplantation
The development of synthetic blood substitutes might make organ transplantation easier and increase the availability of synthetic blood for treating heart attacks and strokes and even reversing death. These techniques have already been tried on pigs, enabling the perfusion of an animal's body via a pump filled with oxygenated blood substitutes that contain a mixture of other chemicals to prevent cell death and aid in healing.
For instance, OrganEx, a Brazilian company, is employing an approach of diluting the blood of the animals by 1:1 with a substitute that contains the right amount of oxygen, acids, and electrolytes, along with 13 drugs.
Thus, such advances in synthetic blood substitutes and blood products lead to an increase in organ transplants and better treatment of heart attacks and strokes, giving hope to people who otherwise would be regarded as beyond medical care, and these factors are driving the market growth.
Financial Challenges and Talent Shortages in the Synthetic Blood Market:
The synthetic blood substitutes and blood product market faces significant financial challenges and a lack of experienced professionals. Research has largely centered on mimicking the oxygen-carrying function of red blood cells.
However, ethical dilemmas such as patient recruitment issues in clinical trials and conflicts of interest have decreased the progress. Both private and public funding for artificial blood research has decreased, leading to layoffs and raising concerns about the future of this field.
Additionally, global financial constraints are worsened by the rising demand for healthcare driven by aging populations and increasing chronic conditions, limiting the available resources for innovation. A skilled workforce is essential to drive advances in healthcare. Still, the difficulties in upskilling current employees and attracting fresh talent to the field pose significant barriers to the continued growth of the synthetic blood substitutes and blood product market.
The Growing Popularity of Synthetically Produced Blood Substitutes
Microorganisms, animal and human blood, stem cells, and even recombinant hemoglobin are some of the sources from which scientists produce artificial blood. One of the most important advantages of synthetic blood is blood type incompatibility, which means that it can be transfused to any patient as it belongs to a universal blood group.
Additionally, artificial blood substitutes do not give rise to any allergy-immunological reactions. Moreover, an artificial blood substitute eliminates the threat of transfusion-associated infectious diseases or contamination, and, like many other artificial products, it has a much longer shelf life. It can be stored at room temperature for more than three years, whereas human blood can only be kept for 42 days.
Because these blood substitutes are easy to store and ideal for use during an emergency, they are also a great option for people whose religion prevents them from accepting donated blood. These are all factors that drive the growth of the market.
The development of synthetic blood substitutes, particularly hemoglobin-based oxygen carriers (HBOCs), is hindered by inconsistent results regarding their effectiveness. Various invasive and non-invasive methods, such as phosphorescence quenching with palladium-porphyrin fiber optics, microelectrodes for oxygen measurement, and electron paramagnetic resonance oximetry, have been used to assess HBOC oxygen delivery. These processes are very complex and cost intensive, increasing overall cost.
Additionally, these blood substitutes are associated with several side effects. Common side effects include transient hypertension, gastrointestinal disturbances, elevated enzyme levels in the pancreas and liver, oxidative stress, cardiac issues, blood clotting problems, neurotoxicity, and renal complications, all of which continue to pose significant challenges in advancing the synthetic blood substitutes and blood product market.
Rising Number of Surgical Procedures
Various surgical strategies are being developed that necessitate synthetic blood substitutes instead of donated human blood plasma or red cells. Increased funding for studies on artificial blood substitutes by means of authorities and personal groups will probably result in improvements and new product launches.
Although minimally invasive operations have decreased the need for blood transfusions, trauma, surgical treatment, orthopedic surgical procedures, and well-known surgical operations all contribute to the requirement for blood and its replacement products. Blood banking is an undersupplied commodity, and the demand for these services keeps rising. Blood and tissue banking are large industries.
Various technical advancements in the synthetic blood product are expected to spur the overall market demand. Healthcare reforms and a growing older population increasing investment in healthcare facilities by various governments are expected to create lucrative opportunities for the market during the forecast period.
Based on type, the Perfluorocarbon-Based Products (PFC) segment dominates the market in 2024 and is expected to remain dominant during the forecast period. Perfluorocarbon-based products such as perfluorodecalin and perfluorobron are preferred for their ability to transport oxygen through the blood flow. The advantages of PFCs in oxygen transport and their role in the market are expected to drive growth in this segment in the forecast period.
The hemoglobin-based oxygen carrier segment is expected to grow at the fastest CAGR during the forecast period. The growing usage of hemoglobin in treating anemia and ischemia is expected to drive its adoption during the forecast period. HBOCs could also be used as an alternative to blood transfusion in emergencies, such as for accident victims, wounded soldiers, or patients having surgery.
Based on end-user, the synthetic blood substitutes and blood product market is segmented into hospitals, clinics, blood banks, and others. Among all these, hospitals and clinics dominated the market in 2024 and are expected to remain dominant during the forecast period.
Various factors, such as increasing usage of synthetic blood substitutes in well-stocked operating rooms, tremendously skilled healthcare experts, personal blood garages and maintenance centres, and a growing number of insurances of healthcare services from non-public and organization coverage, are mainly driving the market growth of this segment during the forecast period.
Report Scope
| Feature of the Report | Details |
| Market Size in 2025 | USD 9,729.94 Million |
| Projected Market Size in 2034 | USD 39,637.49 Million |
| Market Size in 2024 | USD 8,324.01 Million |
| CAGR Growth Rate | 16.89% CAGR |
| Base Year | 2024 |
| Forecast Period | 2025-2034 |
| Key Segment | By Source, Type, Installation Type, End-User and Region |
| Report Coverage | Revenue Estimation and Forecast, Company Profile, Competitive Landscape, Growth Factors and Recent Trends |
| Regional Scope | North America, Europe, Asia Pacific, Middle East & Africa, and South & Central America |
| Buying Options | Request tailored purchasing options to fulfil your research requirements. |
The synthetic blood substitutes and blood product market is segmented by region into North America, Asia Pacific, Europe, the Middle East & Africa, and Latin America. Among all these, North America held the highest market share in 2024 and is expected to remain dominant during the forecast period due to growing investment in the advanced biomedical studies region and enormous healthcare infrastructure.
North America focuses on the safety of affected persons and technological advancements, guaranteeing that artificial blood substitutes are constantly delicate regarding quality and reliability.
The U.S. held a major market share in the region because of its robust investment in research and development and robust aid from regulatory bodies. This rising innovation results in modern-day synthetic blood products that deal with crucial applications in trauma, surgical procedures, and continual disease control.
The U.S. dedication to improving healthcare consequences and showing blood supply shortages drives the adoption of artificial blood substitutes across various medical fields. With a focus on improving hospital treatment and assembling the increasing demand for blood substitutes, the U.S. solidifies its function as a key player in the synthetic blood substitutes and blood product market.
The Asia Pacific region is expected to grow significantly during the forecast period owing to supportive healthcare policies and an increasing number of surgeries across the region. The key countries, such as China, India, Japan, South Korea, and Australia, are mainly driving the market growth of this region.
Source: Custom Market Insights analysis.
To learn more about this report - request a sample report PDF
List of the prominent players in the Synthetic Blood Substitutes and Blood Product Market:
The Synthetic Blood Substitutes and Blood Product Market is segmented as follows:
By Source
By Type
By Installation Type
By End-User
Regional Coverage:
North America
Europe
Asia Pacific
The Middle East & Africa
Latin America
Updated: January 2026 · Formats: PDF, Excel, PPT
Rising awareness of the benefits of artificial blood driving the market growth in the industry.
The "Perfluorocarbon Based Product (PFC)" category dominated the market in 2024.
The key players in the market are Aurum Biosciences Ltd, Baxter International, Dentritech Inc, Hemoglobin Oxygen Therapeutics LLC, HemoBioTech Inc., Hemarina SA, KaloCyte Inc., NuvOx Pharma LLC, SpheriTech Ltd, HemCon Medical Technologies Inc., Matrox Medical Inc., Sorrento Therapeutics Inc., Xeris Pharmaceuticals Inc., BPL Medical Technologies, Sangart Inc., Hemosol Inc., Sonaca Group, The Medicines Company, Erytech Pharma, American Red Cross, Hemerus Medical B.V., Others.
"North America" had the largest share in the Synthetic Blood Substitutes and Blood Product Market.
The global market is projected to grow at a CAGR of 16.89% during the forecast period, 2025-2034.
The Synthetic Blood Substitutes and Blood Product Market size was valued at USD 9,729.94 Million in 2025.
Author · Sr. Research Analyst
Ayush Kadam is a Senior Market Research Analyst at Custom Market Insights, with over seven years of experience in syndicated and custom market research. He specializes in market sizing, competitive intelligence, industry trends, forecasting, and strategic insights, helping clients turn complex data into actionable business decisions.
Buy individual chapters for $490 each: 9 chapters available, from Executive Summary to Company Profiles.
Get the full report structure, sample pages and data tables in the free sample.
Download free sampleGet the full report structure, sample pages and data tables in the free sample.
Download free sampleGet the full report structure, sample pages and data tables in the free sample.
Download free sample